Skip to main content
Top
Published in: Respiratory Research 1/2019

Open Access 01-12-2019 | Sleep Apnea | Letter to the Editor

Relationship between gender and survival in a real-life cohort of patients with COPD

Authors: Maeva Zysman, Pierre-Régis Burgel, Isabelle Court-Fortune, Graziella Brinchault-Rabin, Pascale Nesme-Meyer, Pascale Surpas, Gaetan Deslée, Thierry Perez, Olivier Le Rouzic, Gilles Jebrak, Pascal Chanez, Jean-Louis Paillasseur, Denis Caillaud, Nicolas Roche, on behalf of the Initiatives BPCO scientific committee and investigators

Published in: Respiratory Research | Issue 1/2019

Login to get access

Abstract

Background

Although COPD affects both men and women, its prevalence is increasing more rapidly in women. Disease outcomes appear different among women with more frequent dyspnea and anxiety or depression but whether this translates into a different prognosis remains to be determined. Our aim was to assess whether the greater clinical impact of COPD in women was associated with differences in 3-year mortality rates.

Methods

In the French Initiatives BPCO real-world cohort, 177 women were matched up to 458 menon age (within 5-year intervals) and FEV1 (within 5% predicted intervals). 3-year mortality rate and survival were analyzed. Univariate and multivariate logistic regression analyses were performed.

Results

For a given age and level of airflow obstruction, women with COPD had more severe dyspnea, lower BMI, and were more likely to exhibit anxiety. Nevertheless, three-year mortality rate was comparable among men and women, respectively 11.2 and 10.8%. In a multivariate model, the only factors significantly associated with mortality were dyspnea and malnutrition but not gender.

Conclusion

Although women with COPD experience higher levels of dyspnea and anxiety than men at comparable levels of age and FEV1, these differences do not translate into variations in 3-year mortality rates.

Trial registration

04–479.
Literature
1.
go back to reference Jenkins CR, Chapman KR, Donohue JF, Roche N, Tsiligianni I, Han MK. Improving the management of COPD in women. Chest. 2017;151:686–96.CrossRef Jenkins CR, Chapman KR, Donohue JF, Roche N, Tsiligianni I, Han MK. Improving the management of COPD in women. Chest. 2017;151:686–96.CrossRef
2.
go back to reference Han MK, Arteaga-Solis E, Blenis J, Bourjeily G, Clegg DJ, DeMeo D, et al. Female sex and gender in lung/sleep health and disease. Increased understanding of basic biological, pathophysiological, and behavioral mechanisms leading to better health for female patients with lung disease. Am J Respir Crit Care Med. 2018;198:850–8.CrossRef Han MK, Arteaga-Solis E, Blenis J, Bourjeily G, Clegg DJ, DeMeo D, et al. Female sex and gender in lung/sleep health and disease. Increased understanding of basic biological, pathophysiological, and behavioral mechanisms leading to better health for female patients with lung disease. Am J Respir Crit Care Med. 2018;198:850–8.CrossRef
3.
go back to reference Chapman KR, Tashkin DP, Pye DJ. Gender bias in the diagnosis of COPD. Chest. 2001;119:1691–5.CrossRef Chapman KR, Tashkin DP, Pye DJ. Gender bias in the diagnosis of COPD. Chest. 2001;119:1691–5.CrossRef
4.
go back to reference Amaral AFS, Strachan DP, Burney PGJ, Jarvis DL. Female smokers are at greater. Risk of airflow obstruction than male smokers. UK biobank. Am J Respir Crit Care Med. 2017;195:1226–35.CrossRef Amaral AFS, Strachan DP, Burney PGJ, Jarvis DL. Female smokers are at greater. Risk of airflow obstruction than male smokers. UK biobank. Am J Respir Crit Care Med. 2017;195:1226–35.CrossRef
5.
go back to reference Naberan K, Azpeitia A, Cantoni J, Miravitlles M. Impairment of quality of life in women with chronic obstructive pulmonary disease. Respir Med. 2012;106:367–73.CrossRef Naberan K, Azpeitia A, Cantoni J, Miravitlles M. Impairment of quality of life in women with chronic obstructive pulmonary disease. Respir Med. 2012;106:367–73.CrossRef
6.
go back to reference Raherison C, Tillie-Leblond I, Prudhomme A, Taillé C, Biron E, Nocent-Ejnaini C, et al. Clinical characteristics and quality of life in women with COPD: an observational study. BMC Womens Health. 2014;14:31.CrossRef Raherison C, Tillie-Leblond I, Prudhomme A, Taillé C, Biron E, Nocent-Ejnaini C, et al. Clinical characteristics and quality of life in women with COPD: an observational study. BMC Womens Health. 2014;14:31.CrossRef
7.
go back to reference DeMeo DL, Ramagopalan S, Kavati A, Vegesna A, Han MK, Yadao A, et al. COPDGene investigators. Women manifest more severe COPD symptoms across the life course. Int J Chron Obstruct Pulmon Dis. 2018;13:3021–9.CrossRef DeMeo DL, Ramagopalan S, Kavati A, Vegesna A, Han MK, Yadao A, et al. COPDGene investigators. Women manifest more severe COPD symptoms across the life course. Int J Chron Obstruct Pulmon Dis. 2018;13:3021–9.CrossRef
8.
go back to reference Aryal S, Diaz-Guzman E, Mannino DM. Influence of sex on chronic obstructive pulmonary disease risk and treatment outcomes. Int J Chron Obstruct Pulmon Dis. 2014;9:1145–1154.12.PubMedPubMedCentral Aryal S, Diaz-Guzman E, Mannino DM. Influence of sex on chronic obstructive pulmonary disease risk and treatment outcomes. Int J Chron Obstruct Pulmon Dis. 2014;9:1145–1154.12.PubMedPubMedCentral
9.
go back to reference Nishimura K, Izumi T, Tsukino M, Oga T, on Behalf of the Kansai COPD Registry and Research Group in Japan. Dyspnea is a better predictor of 5-yearsurvival than airway obstruction in patients with COPD. Chest. 2002;121:1434–40.CrossRef Nishimura K, Izumi T, Tsukino M, Oga T, on Behalf of the Kansai COPD Registry and Research Group in Japan. Dyspnea is a better predictor of 5-yearsurvival than airway obstruction in patients with COPD. Chest. 2002;121:1434–40.CrossRef
10.
go back to reference Celli B, Vestbo J, Jenkins CR, Jones PW, Ferguson GT, Calverley PM, et al. Investigators of the TORCH Study. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. Am J Respir Crit Care Med. 2011;183:317–22.CrossRef Celli B, Vestbo J, Jenkins CR, Jones PW, Ferguson GT, Calverley PM, et al. Investigators of the TORCH Study. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. Am J Respir Crit Care Med. 2011;183:317–22.CrossRef
11.
go back to reference Di Marco F, Verga M, Reggente M, Maria Casanova F, Santus P, Blasi F, et al. Anxiety and depression in COPD patients: the roles of gender and disease severity. Respir Med. 2006;100:1767–74.CrossRef Di Marco F, Verga M, Reggente M, Maria Casanova F, Santus P, Blasi F, et al. Anxiety and depression in COPD patients: the roles of gender and disease severity. Respir Med. 2006;100:1767–74.CrossRef
12.
go back to reference Roche N, Deslée G, Caillaud D, Brinchault G, Court-Fortune I, Nesme-Meyer P, Surpas P, Escamilla R, Perez T, Chanez P, Pinet C, Jebrak G, Paillasseur JL, Burgel PR, INITIATIVES BPCO Scientific Committee. Impact of gender on COPD expression in a real-life cohort. Respir Res. 2014;15:20.CrossRef Roche N, Deslée G, Caillaud D, Brinchault G, Court-Fortune I, Nesme-Meyer P, Surpas P, Escamilla R, Perez T, Chanez P, Pinet C, Jebrak G, Paillasseur JL, Burgel PR, INITIATIVES BPCO Scientific Committee. Impact of gender on COPD expression in a real-life cohort. Respir Res. 2014;15:20.CrossRef
13.
go back to reference Burgel PR, Paillasseur JL, Caillaud D, Tillie-Leblond I, Chanez P, Escamilla R, Court-Fortune I, Perez T, Carré P, Roche N, Initiatives BPCO ScientificCommittee. Clinical COPD phenotypes: a novel approach using principal componentand cluster analyses. Eur Respir J. 2010;36:531–9.CrossRef Burgel PR, Paillasseur JL, Caillaud D, Tillie-Leblond I, Chanez P, Escamilla R, Court-Fortune I, Perez T, Carré P, Roche N, Initiatives BPCO ScientificCommittee. Clinical COPD phenotypes: a novel approach using principal componentand cluster analyses. Eur Respir J. 2010;36:531–9.CrossRef
14.
go back to reference Lahousse L, Seys LJM, Joos GF, Franco OH, Stricker BH, Brusselle GG. Epidemiology and impact of chronic bronchitis in chronic obstructive pulmonary disease. Eur Respir J. 2017;50:1602470.CrossRef Lahousse L, Seys LJM, Joos GF, Franco OH, Stricker BH, Brusselle GG. Epidemiology and impact of chronic bronchitis in chronic obstructive pulmonary disease. Eur Respir J. 2017;50:1602470.CrossRef
15.
go back to reference Prudente R, Franco EAT, Mesquita CB, Ferrari R, de Godoy I, Tanni SE. Predictors of mortality in patients with COPD after 9 years. Int J Chron Obstruct Pulmon Dis. 2018;17(13):3389–98.CrossRef Prudente R, Franco EAT, Mesquita CB, Ferrari R, de Godoy I, Tanni SE. Predictors of mortality in patients with COPD after 9 years. Int J Chron Obstruct Pulmon Dis. 2018;17(13):3389–98.CrossRef
16.
go back to reference de Torres JP, Cote CG, López MV, Casanova C, Díaz O, Marin JM, et al. Sex differences in mortality in patients with COPD. Eur Respir J. 2009;33:528–35.CrossRef de Torres JP, Cote CG, López MV, Casanova C, Díaz O, Marin JM, et al. Sex differences in mortality in patients with COPD. Eur Respir J. 2009;33:528–35.CrossRef
Metadata
Title
Relationship between gender and survival in a real-life cohort of patients with COPD
Authors
Maeva Zysman
Pierre-Régis Burgel
Isabelle Court-Fortune
Graziella Brinchault-Rabin
Pascale Nesme-Meyer
Pascale Surpas
Gaetan Deslée
Thierry Perez
Olivier Le Rouzic
Gilles Jebrak
Pascal Chanez
Jean-Louis Paillasseur
Denis Caillaud
Nicolas Roche
on behalf of the Initiatives BPCO scientific committee and investigators
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2019
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-019-1154-3

Other articles of this Issue 1/2019

Respiratory Research 1/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine